Plant Products winds down distribution of Syngenta greenhouse vegetable seeds

Feb 07, 2024

Syngenta Vegetable Seeds Global and Plant Products have concluded their 15-year North American greenhouse vegetable seed supply and distribution partnership.

Beginning in February 2024, Plant Products will no longer be involved in those activities -- new product development, demand creation, technical support, complaint management, logistics, import permitting, or accounts receivable -- in support of the Syngenta greenhouse vegetable seed business in Canada or the United States. But the company is actively pursuing a partnership agreement with other greenhouse vegetable seed suppliers in the future.

“We’re very proud of the results Plant Products has produced on behalf of Syngenta since our collaboration began,” noted Chris Stickles, president of Plant Products. “Together, we were able to bring value to and support Plant Products’ customers.”

Plant Products remains committed to participating in the greenhouse vegetable seeds business going forward.

Source : The Grower

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.